Heart Failure

From newsworthy moments to groundbreaking research, these were the most-read heart failure-related articles on Pharmacy Times in 2023.

In a study, most patients had specified SBP targets of less than 160 mmHg and all patients attained goal within a relatively short period of time.

The results of the study show the importance of considering neighborhood-level disparities to address and improve medication adherence, according to investigators.

Individuals received 4 daily short messages that reminding them to participate in self-care, active engagement, and early intervention for the first 30 days of the study.

Investigators also found that the results demonstrated lower death and hospitalization rates for those with advanced heart failure treated with cell therapy.

In mice with heart failure, radiation therapy demonstrated improved heart function, specifically in the left ventricle, and reduced inflammation in the heart.

Although involvement of a cardiologist for heart failure has been associated with reduced rates of in-hospital mortality, not all patients see a cardiologist when hospitalized, according to the investigators.

Heart failure is a major cause of morbidity and mortality for adults with congenital heart disease (CHD), with the highest risk being for those with complex CHD lesions.

Major barriers to care for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) can include navigating therapeutics and the cost of medications.

Improvements were seen in left ventricular ejection fraction, NYHA Functional Class, and Minnesota Living with Heart Failure Questionnaire at 1-year post-dose.

In human heart tissues, investigators found that the mechanism associated with heart failure can be reversed and Dicer activity can be restored when AD-9308 was used.

Regular usage of cannabis may increase the risk of heart failure, stroke, or heart attack, even after adjusting for other cardiovascular disease risk factors.

Risk of atrial fibrillation with 1 of the independent predictors, including congestive heart failure and left atrial enlargement, resulted in greater than a 4-fold increased detection.

Although SGLT2 inhibitors are not a cure of diabetic kidney disease, this treatment can help reduce the risk and manage the disease either alone or with complementary therapies.

How pharmacy teams can remove cost barriers to cardiac care.

Anemic individuals with heart failure with preserved ejection fraction displayed unique pathophysiological features that led to reduced exercise capacity.

Sotagliflozin (Inpefa) is an orally administered dual SGLT1/2 inhibitor that reduces the risk of death due to heart failure.

BMS-986278 (Bristol Myers Squibb) is a potential first-in-class treatment for progressive pulmonary fibrosis and idiopathic pulmonary fibrosis.

This marks the first time that experts have defined cardiovascular-kidney-metabolic syndrome, including the overlap of cardiovascular disease with kidney disease, type 2 diabetes, and obesity.

Patients under the care of psychiatric facilities, particularly those taking antipsychotic and antidepressant medications, face the risk of prolonged QTc intervals.

Study findings indicated that many health care facilities are recovering from the COVID-19 pandemic and shortage of staff, which has caused door-to-balloon times to lag.

Routine yoga therapy has shown endurance, strength, balance, symptom stability and quality of life improvements in individuals with heart failure.

An average patient with heart failure can take up to 6 medications for guideline-directed medical therapy; however, they may have other comorbidities that require pharmacologic management.

Heart disease prevention efforts should acknowledge non-biological factors that can cause issues within cardiovascular health rather than relying on decreasing socioeconomic disparities.

The Phase 2 KARDIA-1 Study met its primary endpoint of lower systolic blood pressure with the use of zilebesiran.